NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Thailand Inflation Remains Negative for 10th Straight Month in January 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
